Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib cardiovascular outcomes study in ASCVD
NL-OMON53473Phase 3Recruiting
- Sponsor
- NewAmsterdam Pharma
- Start
- Jun 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and hypercholesterolemia comparing Obicetrapib 10 mg once daily with Placebo once daily (2 arms). Primary endpoints: Time to first major adverse cardiovascular event and Safety and tolerability. Started Jun 2022; status: recruiting.
02
Drugs
obicetrapib
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on NL-OMON53473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53473.